Pacific Biosciences of California (NASDAQ: PACB) no doubt made many investors happy in 2020, as its shares more than quintupled in value. The genetic sequencing systems stock is off to a great start in 2021 as well, with a year-to-date gain of 80%.
The good times should keep rolling for PacBio. The company announced its fourth-quarter results after the market closed on Wednesday. Here are the highlights from PacBio’s Q4 update.